Management

Company

Board
Management
IPR
Collaborations

Pharma Holdings Management

Pharma Holdings is a small and cost-effective company without its own laboratories or research facilities, using a network of high-quality contract research organizations and contract manufacturing organizations. The company has experienced advisors in all critical functions such as product development, regulatory affairs, design and execution of clinical trials. Agir AS is retained for administration and project management.

Christian Lütken, CEO

Christian Lütken holds an MD from the University of Oslo and has several
years of experience in the fields of pediatrics, family medicine, emergency medicine and occupational medicine. He has management experience as previous Head of Department in a private healthcare company. In recent years Christian has been working in DNB’s Global Healthcare team financing healthcare companies globally, and also working closely with the Norwegian healthcare startup scene comprising all subsegments of the healthcare industry including med.tech, pharma, bio tech, digital health and healthcare services.

Torstein Erlingsson, CFO

Mr. Erlingsson has been with Pharma Holdings AS since 2018. He holds a
Master Science degree in Fishery Science from UiT, the Arctic University of Norway. He has more than 25 years of experience from corporate finance and business development. In his tenure in corporate finance Erlingsson worked on several biotech transactions, and in Pharma Holdings Mr. Erlingsson has secured equity financing for the relaunch of the development of our lead drug candidate.

Johnny Ryvoll, Vice President Business Developer

Mr. Ryvoll has been with Pharma Holdings since 2018. He holds a MBA from University of Washington, Foster School of Business, and also a degree in Electrical Engineering (Siv. Ing.). He has more than 25 years of experience from corporate finance, project management and business development. In his tenure in corporate finance Mr. Ryvoll worked on several biotech transactions. In his time in Pharma Holdings he has built a network of high-quality contract research organizations and contract manufacturing capacity as well as networks of experienced advisors in all critical functions for the company such as product development, regulatory affairs, design and execution of clinical trials.

Rof EngstadContracted CMC Lead

Rolf E. Engstad holds a PhD in immunology from the University of Tromsø and has more than 30 years of experience in research and development of pharmaceutical product candidates. He is approved as a qualified person (QP) and has been responsible for securing the manufacture and the pharmaceutical quality of clinical trial products.
Engstad was chief scientific officer (CSO) in Biotec Pharmacon for almost 20 years and in charge of the successful development of pharmaceutical and medical device products, as well as responsible for pre-clinical and clinical studies. He has longstanding research collaborations with international institutions like the Charité in Berlin, the Memorial Sloan Kettering Cancer Centre, and the Mount Sinai Hospital, both New York, as well as with many Norwegian universities and research institutes. Engstad is also the inventor of more than 20 granted patents and patent applications.